Study on Long-term Immunogenicity of COVID-19 vaccines in vaccine-naÃ?Â¯ve seronegative and seropositive participants - VISION 101

ational Centre for Biological Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Between the ages of 18 and 45, both inclusive
•2.Permanent residents of the selected localities where community outreach is routine
•3.Only one member from a household will be selected.
•4.Either a) sero-negativity or b) sero-positivity to SARS-CoV-2 with or without a history of clinical illness suggestive of COVID-19 or confirmed COVID-19 in the past (either mild or moderate infection)

•1.Participant failure to consent.
•2.Acute febrile illness in the participant at the time of the recruitment.
•3.Active cancers or bleeding disorders
•4.Individuals with a history of severe COVID-19 that required ventilation or received either convalescent plasma or monoclonal antibody treatments.
•5.Any medical condition in the participant, which, in the judgment of the investigator, would interfere with protocol adherence.

发起方

ational Centre for Biological Sciences